How Does Dorzolamide Work? Mechanism of Action Explained in Plain English

If you've ever wondered why your eye doctor prescribed a specific medication for glaucoma — or what's actually happening inside your eye when you use dorzolamide — this guide is for you. Understanding how your medication works can make it easier to take it consistently and understand why it matters.

First, What Is Intraocular Pressure and Why Does It Matter?

Your eyes contain fluid called aqueous humor. This clear fluid is continuously produced in a part of the eye called the ciliary body, flows through the eye, and drains out through a tiny drainage canal. Think of it like a sink — fluid flowing in and draining out.

In healthy eyes, this inflow and outflow stay in balance, maintaining a stable pressure (called intraocular pressure, or IOP) typically between 10-21 mmHg. When the drainage canal becomes partially blocked — or when too much fluid is produced — pressure builds up.

Elevated IOP is the main risk factor for glaucoma, a disease where pressure damages the optic nerve (the nerve that carries visual information from your eye to your brain). The damage is irreversible. That's why controlling IOP is the core goal of glaucoma treatment.

What Is Carbonic Anhydrase — and Why Block It?

Inside the ciliary body (the part of your eye that produces aqueous humor), there is an enzyme called carbonic anhydrase. Enzymes are biological catalysts — proteins that speed up specific chemical reactions in your body.

Carbonic anhydrase's job in the eye is to help convert carbon dioxide (CO₂) and water (H₂O) into bicarbonate (HCO₃⁻) and a hydrogen ion (H⁺). This reaction is central to aqueous humor production because it drives a sodium-hydrogen ion exchange that ultimately pumps fluid into the eye.

In plain English: carbonic anhydrase acts like a switch that turns on aqueous humor production. Block the enzyme, and less fluid is made.

How Dorzolamide Targets the Right Enzyme

There are multiple forms ("isoforms") of carbonic anhydrase in the body — labeled CA-I, CA-II, CA-IV, CA-XII, and others. The one most responsible for aqueous humor production in the eye is carbonic anhydrase II (CA-II).

Dorzolamide is a highly selective inhibitor of CA-II. In fact, it has approximately 4,000 times greater affinity for CA-II than for CA-I. This specificity is important because it allows dorzolamide to target the mechanism of aqueous production in the eye without having to block carbonic anhydrase everywhere in the body (which would cause more systemic side effects).

Dorzolamide was notable as the first drug ever developed using structure-based drug design — a technique where scientists design molecules specifically to fit the shape of a target enzyme, like designing a key to fit a lock. This innovation, led by Merck in the 1990s, marked a turning point in pharmaceutical development.

How Much Does Dorzolamide Lower Eye Pressure?

Dorzolamide reduces intraocular pressure by approximately 20% when used as a single agent (monotherapy). In one clinical study, latanoprost reduced mean baseline IOP by 8.5 mmHg compared to 5.6 mmHg for dorzolamide — a reminder that dorzolamide is typically used as an add-on therapy or for patients who cannot tolerate prostaglandin analogs.

Effects begin within about 3 hours of the first dose and last approximately 8 hours — which is why three-times-daily dosing is necessary for continuous 24-hour pressure control.

What Happens After the Drop Enters the Eye?

After you instill the drop, dorzolamide is absorbed through the cornea and enters the aqueous humor. It binds to CA-II in the ciliary epithelium and blocks its activity. The result: reduced bicarbonate production, reduced sodium and water transport into the eye, and a lower rate of aqueous humor secretion.

Some dorzolamide is also absorbed systemically — it enters the bloodstream through the nasolacrimal duct and the conjunctival blood vessels. Once in the blood, it accumulates in red blood cells (where CA-II is also present). This is why plasma concentrations are low (generally under 15 nM) but the drug can still be detected in the body during long-term use. The systemic levels are generally too low to cause meaningful effects in healthy individuals.

How Dorzolamide Compares to Other Glaucoma Drug Classes

To understand dorzolamide's role, it helps to compare it to other IOP-lowering mechanisms:

• Prostaglandin analogs (latanoprost, bimatoprost): Increase drainage of aqueous humor through an alternate pathway (uveoscleral outflow). Reduce IOP by ~25-30%. Used once daily.
• Beta-blockers (timolol): Block beta-adrenergic receptors in the ciliary body, reducing fluid production. Reduce IOP by ~20-25%. Used once or twice daily.
• Carbonic anhydrase inhibitors (dorzolamide, brinzolamide): Block CA-II to reduce aqueous humor production. Reduce IOP by ~20%. Used three times daily. Often added to therapy when first-line agents are insufficient.
• Alpha-agonists (brimonidine): Both reduce fluid production and increase outflow. Used 2-3 times daily.

For the full patient overview of dorzolamide — including dosing, cost, and how to take it — see our guide What Is Dorzolamide?. If you're having trouble finding it in stock at your pharmacy, medfinder can help.